Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151426 | 0.81 | SSTR4 (0.41) | SSTR4CNR2MAPTNPC1RAB9A | |
| SCHEMBL3440172 | 0.81 | SSTR4 (0.44) | SSTR4S100A4CNR2MAPTNPC1 | |
| SCHEMBL634567 | 0.80 | SSTR4 (0.43) | SSTR4S100A4CNR2MAPTNPC1 | |
| SCHEMBL633518 | 0.77 | SSTR4 (0.38) | SSTR4CNR2MAPTNPC1RAB9A | |
| SCHEMBL12818069 | 0.67 | SMN1; SMN2 (0.50) | SSTR4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16892961 | 0.67 | SMN1; SMN2 (0.42) | SSTR4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL132212 | 0.67 | SSTR4 (0.44) | SSTR4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29676258 | 0.67 | SSTR4 (0.58) | SSTR4CNR2MAPTNPC1RAB9A | |
| SCHEMBL13151418 | 0.66 | SSTR4 (0.43) | SSTR4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20837204 | 0.66 | KCNN4 (0.48) | MAPTSMN1; SMN2KDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| WO-2010118852-A1 | ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | H1-3, CHRM2, TBL3 | SSTR4 2701/4885S100A4 4030/4885CNR2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.